VCEL Vericel Corp
Q3 2025 10-Q
Filed: Nov 6, 2025Period ending Sep 30, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR Vericel Corp (VCEL) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Risk Factors
- • New FDA operational risk from 2025 federal employee layoffs affecting review of MACI Ankle IND and clinical trial enrollment start in H2 2025
- • Most material update: disruptions and leadership resignations at FDA causing potential delays in inspections and approvals of manufacturing facilities
Quarterly Financial SummaryXBRL
Revenue
$68M
▲ +16.6% YoY▲ +6.7% QoQ
Net Income
$5M
▲ +663.2% YoY▲ +1017.5% QoQ
Gross Margin
73.5%
▲ +152bp YoY▼ -25bp QoQ
Operating Margin
5.1%
▲ +937bp YoY▲ +832bp QoQ
Net Margin
7.5%
▲ +907bp YoY▲ +839bp QoQ
ROE
1.6%
Total Assets
$453M
EPS (Diluted)
$0.11
▲ +1200.0% YoY▲ +1200.0% QoQ
Operating Cash Flow
$22M
▲ +116.8% YoY▲ +168.8% QoQ
Source: XBRL data from Vericel Corp Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Vericel Corp
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.